Arthralgia during aromatase inhibitor treatment in early breast cancer patients: Prevalence, impact, and recognition by healthcare providers

Cancer Nursing

Volumn 36, Issue 1, 2013, Pages 52-59

  Boonstra, Amilie ^a   Van Zadelhoff, Joost ^b   Timmer Bonte, Anja ^a   Ottevanger, Petronella B ^a   Beurskens, Carien H G ^b   Van Laarhoven, Hanneke W M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adherence; Aromatase inhibitors; Arthralgia; Breast cancer; Musculoskeletal symptoms; Quality of life

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ADULT; ARTHRALGIA; BREAST CANCER; CANCER PATIENT; CLINICAL PRACTICE; DAILY LIFE ACTIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GONIOMETRY; GRIP STRENGTH; HAND FUNCTION; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PAIN ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RANGE OF MOTION; REVIEW; TREATMENT DURATION; WRIST;

AGED; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; FEMALE; HAND STRENGTH; HEALTH PERSONNEL; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; PAIN MEASUREMENT; WRIST;

EID: 84871623196     PISSN: 0162220X     EISSN: 15389804     Source Type: Journal    
DOI: 10.1097/NCC.0b013e31824a7e18     Document Type: Review

References (35)

1. Din OS, Dodwell D, Wakefield RJ, et al. Aromatase inhibitorYinduced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat. 2010;120:525-538.
2. De vereniging van intergrale kankercentra. http://www. ikcnet. nl/. Accessed October 4, 2010.
3. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.
4. Khan QJ, O'Dea AP, Sharma P. Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol. 2010;2010. pii:654348.
5. Amir E, Ocaña A, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients. Abstract presented at the San Antonio Breast Cancer Symposium, September 12, 2010.
6. Younus J, Kligman L. Management of aromatase inhibitorYinduced arthralgia. Curr Oncol. 2010;17:87-90.
7. Burstein HJ. Aromatase inhibitorYassociated arthralgia syndrome. Breast. 2007;16:223-234.
8. Cella D, Fallowfield L, Barker P, et al. Quality of life of postmenopausal women in the ATAC ("Arimidex, " Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100:273-284.
9. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA. 17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23:6931-6940.
10. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 2006;24:910-917.
11. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25:3877-3883.
12. Presant CA, Bosserman L, Young T, et al. Aromatase inhibitorYassociated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer. 2007;7:775-778.
13. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients. J Clin Oncol. 2010;28:4120-4128.
14. Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26:556-562.
15. Stucki G, Liang MH, Stucki S, et al. A self-administered Rheumatoid Arthritis Disease Activity Index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. Arthritis Rheum. 1995;38:795-798.
16. Fallowfield LJ, Leaity SK, Howell A, et al. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat. 1999;55:189-199.
17. Owners' Manual JAMAR Hydrolic Hand Dynamometer. http://www. handyhealthcare. co. uk/media/product/pdf/jamar-hydraulic-handdynamometer- instructions. pdf. Accessed September 16, 2010.
18. Mathiowetz V, Weber K, Volland G, et al. Reliability and validity of grip and pinch strength evaluations. J Hand Surg Am. 1984;9:222-226.
19. Morales L, Pans S, Verschueren K, et al. Prospective study to assess shortterm intra-articular and tenosynovial changes in the aromatase inhibitorY associated arthralgia syndrome. J Clin Oncol. 2008;26:3147-3152.
20. Werle S, Goldhahn J, Drerup S, et al. Age-and gender-specific normative data of grip and pinch strength in a healthy adult Swiss population. J Hand Surg Eur. 2009;34(1):76-84.
21. Carter TI, Pansy B, Wolff AL, et al. Accuracy and reliability of three different techniques for manual goniometry for wrist motion: a cadaveric study. J Hand Surg Am. 2009;34:1422-1428.
22. Luttgens K, Hamilton N. Kinesiology: Scientific Basis of Human Motion. Madison, WI: Brown & Benchmark; 1997.
23. Riemsma RP, Taal E, Rasker JJ, et al. Evaluation of a Dutch version of the AIMS2 for patients with rheumatoid arthritis. Br J Rheumatol. 1996;35:755-760.
24. Tait RC, Pollard CA, Margolis RB, et al. The Pain Disability Index: psychometric and validity data. Arch Phys Med Rehabil. 1987;68:438-441.
25. Horne R, Hankins M, Jenkins R. The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Healthc. 2001;10:135-140.
26. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092.
27. Sestak I, Cuzick J, Sapunar F, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008;9:866-872.
28. Kulie T, Slattengren A, Redmer J, et al. Obesity and women's health: an evidence-based review. J Am Board Fam Med. 2011;24:75-85.
29. Christensen R, Astrup A, Bliddal H. Weight loss: the treatment of choice for knee osteoarthritis? A randomized trial. Osteoarthritis Cartilage. 2005; 13:20-27.
30. Courtney MR, Conard SE, Dunn P, et al. The Game of Health(c): an innovative lifestyle change program implemented in a family practice. J Am Acad Nurse Pract. 2011;23:289-297.
31. Makubate B, McCowan C, Dewar JA, et al. Completion of 5-years adjuvant endocrine therapy in the community. Abstract presented at the San Antonio Breast Cancer Symposium. November 12, 2010.
32. Winters L, Habin K, Flanagan J, et al. "I feel like I am 100 years old!" managing arthralgias from aromatase inhibitors. Clin J Oncol Nurs. 2010; 14:379-382.
33. Miaskowski C, Shockney L, Chlebowski RT. Adherence to oral endocrine therapy for breast cancer: a nursing perspective. Clin J Oncol Nurs. 2008;12:213-221.
34. Magliano M. Menopausal arthralgia: fact or fiction. Maturitas. 2010;67: 29-33.
35. Mercadante S. Management of cancer pain. Intern Emerg Med. 2010; 5(suppl 1):S31YS35.